Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.

Abstract

Pembrolizumab is an immune checkpoint inhibitor used in many cancer types, including genitourinary cancers. Although immunotherapies have dramatically changed the landscape of cancer treatment by providing an alternative to traditional chemotherapy, they have been associated with significant immune-related adverse events (IRAEs) with wide-ranging clinical manifestations. We present the case of an elderly woman on pembrolizumab for metastatic bladder cancer who developed cutaneous IRAE with lichenoid eruptions that responded to high-dose intravenous glucocorticoids.

• Authors: Benjamin Joseph McCormick, Daniel Zieman, Cassidy West-Santos, Michael B Phillips
• Journal: BMJ case reports (BMJ Case Rep) Vol. 16 Issue 6 (Jun 20 2023) ISSN: 1757-790X [Electronic] England
• PMID: 37339826 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• pembrolizumab
• Immune Checkpoint Inhibitors
• Antibodies, Monoclonal, Humanized

Topics

• Female
• Humans
• Aged
• Immune Checkpoint Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Lichenoid Eruptions (chemically induced, drug therapy)
• Neoplasms (drug therapy)